Literature DB >> 7490015

[Enzyme-linked immunoadsorbent assays for myelin basic protein and antibodies to myelin basic protein in serum and CSF of patients with diseases of the nervous system].

R Wang1, J Chen, S Zhou, C Li, G Yuan, W Xu, X Wang, J Li, Y Song, N Gong.   

Abstract

Simplified enzyme-linked immunoadsorbent assays (ELISA) for myelin basic protein (MBP) and antibodies to myelin basic protein (Anti-MBP) have been used to test 337 patients with diseases of the nervous system including 36 compressive diseases (CMP), 33 multiple sclerosis (MS), 34 cerebrovascular diseases (CVD), 31 inflammatory diseases of central nervous system (ID), 161 epilepsy (EP) and 42 other nervous diseases (OND). Comparison of results among various groups indicates that serum mean MBP values of CMP, MS, CVD, ID and EP groups are significantly higher than those of OND group and normal control (P < 0.01). The serum mean MBP value of 33 acute trauma patients with spine fracture and paraplegia, the majority of CMP group, is the highest compared with MS group (P < 0.05), CVD, ID and EP groups (P < 0.01). CSF mean MBP value of 15 CVD patients is markedly greater than that of OND group (P < 0.05). No statistically significant differences are found in serum MBP values between OND group and normal control, and in serum and CSF Anti-MBP values among six groups by using our method.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490015

Source DB:  PubMed          Journal:  Hua Xi Yi Ke Da Xue Xue Bao        ISSN: 0257-7712


  2 in total

Review 1.  Molecular diagnostics in neurotrauma: Are there reliable biomarkers and effective methods for their detection?

Authors:  Davran Sabirov; Sergei Ogurcov; Irina Baichurina; Nataliya Blatt; Albert Rizvanov; Yana Mukhamedshina
Journal:  Front Mol Biosci       Date:  2022-09-29

2.  Antibody profiling identifies novel antigenic targets in spinal cord injury patients.

Authors:  Ilse Palmers; Elke Ydens; Eric Put; Bart Depreitere; Helma Bongers-Janssen; Peter Pickkers; Sven Hendrix; Veerle Somers
Journal:  J Neuroinflammation       Date:  2016-09-13       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.